Intercept Seeks Long-Term Data To Build Ocaliva Market In PBC

The FXR agonist is the first new drug approved for primary biliary cholangitis in 19 years, but the lack of long-term outcomes data leaves a perceived opportunity for a host of mid-stage candidates also pursuing the indication. Intercept is conducting a Phase IV study to obtain such data with Ocaliva.

BOSTON – Ocaliva (obeticholic acid) became the first new drug to market for primary biliary cholangitis (PBC) in 19 years with its June launch in the US, but its indication as second-line therapy in a chronic condition left lots of treatment questions and potential safety gaps for other PBC candidates to target. Intercept Pharmaceuticals Inc. CEO Mark Pruzanski explained in a Nov. 15 interview during the American Association for the Study of Liver Diseases meeting that his company is working toward long-term outcomes data that might mitigate some of those perceived gaps.

Ocaliva is a bile acid analog that inhibits the farnesoid X receptor (FXR) and is in Phase III development for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By 

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.